Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation.

Abstract

BACKGROUND:

Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies.

CASE REPORT:

A patient with liver metastases from BC was treated with peptide receptor radionuclide therapy (PRRT). Computed tomography scan and biochemical examinations showed a clear response to radionuclide therapy.

CONCLUSION:

PRRT may be useful in metastatic BC patients.

• Authors: Giordano Savelli, Alberto Zaniboni, Francesco Bertagna, Giovanni Bosio, Lutfun Nisa, Carlo Rodella, Giorgio Biasiotto, Giovanni Bettinsoli, Elena Migliorati, Alessia Peli, Roberta Falchi, Francesca Giuffrida, Raffaele Giubbini
• Journal: Breast care (Basel, Switzerland) (Breast Care (Basel)) Vol. 7 Issue 5 Pg. 408-10 (Oct 2012) ISSN: 1661-3791 [Print] Switzerland
• PMID: 24647781 (Publication Type: Case Reports)